CASI Pharmaceuticals, Inc.
About CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced FDA clearance of an IND application for CID-103, an anti-CD38 monoclonal antibody in adults with active and chronic active renal allograft antibody mediated rejection (AMR). The Phase 1 clinical trial is a dose-ranging and safety study evaluating the tolerability and efficacy of CID-103 in patients with AMR.
Find CASI Pharmaceuticals, Inc. Execs' Valid Emails
Up to 90% verified emails and mobile numbers, refreshed weekly.
Company Details
25M-75M
Biotechnology Research
51-200 employees
Public Company
San Francisco, CA
United States
Frequently Asked Questions about
What is CASI Pharmaceuticals, Inc.'s industry?
CASI Pharmaceuticals, Inc. operates in the Biotechnology Research industry and is headquartered in United States.
How many employees does CASI Pharmaceuticals, Inc. have?
CASI Pharmaceuticals, Inc. has approximately 51-200 employees employees.
Where is CASI Pharmaceuticals, Inc.'s based?
CASI Pharmaceuticals, Inc. is based in San Francisco, CA, United States.
Is CASI Pharmaceuticals, Inc. publicly listed?
Yes. CASI Pharmaceuticals, Inc. is a publicly traded company.
How can I contact CASI Pharmaceuticals, Inc.'s investor relations team?
You can reach CASI Pharmaceuticals, Inc.’s investor relations department through the contact section on their official website or directly via the investor relations email listed in their latest SEC filings.
Find verified emails and phone numbers for professionals like those at
Up to 90% verified emails and mobile numbers, backed by weekly job-change alerts.
Find verified emails at this company
An email pattern tells you the format. It does not tell you who works there now or whether an address still delivers. Scalelist returns verified contacts, checked at the point you build the list.